5-hydroxytryptamine (5-HT)3 receptor binding assay using
ABSTRACT-The 5-hydroxytryptamine (5-HT)3 receptor binding assay using
[3H]quipazine was examined. It was impossible to obtain specific [3H]quipazine bind ing with the membrane fractions from rat cortex prepared by the usual procedure. When the membranes were pretreated with detergent Triton X-100, the ratio of spe cific [3H]quipazine binding markedly increased, depending upon the concentration of Triton X-100 in the range of 0.01-0.1% (w/v). At a concentration of more than 0.05%, the specific binding reached a maximum of 55 to 60% of the total binding. The specific [3H]quipazine binding to the Triton X-100-treated membranes was re versible and was potently inhibited by several 5-HT3 antagonists, while 5-HT], 5-HT2 receptor antagonists and other receptor-specific ligands had no effect on the binding. Peroutka and Hamik (7) have reported that [3H]quipazine, a commercially available radio ligand, has a high affinity for 5-HT3 binding sites in rat cortical membranes. However, we have been unsuccessful in attempts to obtain highly specific [3H]quipazine binding using their method, because of high percentages of non-specific binding. To obtain 5-HT3 recep tor preparations with a high affinity for [3H]quipazine, we performed various addition al treatments on the membranes; and inter estingly, we found that the specific binding of [3H]quipazine increased markedly when the membranes were treated with Triton X-100 (polyethylene glycol p-isooctylphenyl ether).
In the present paper, we describe a reliable method for 5-HT3 receptor binding assay with
[3H]quipazine using Triton X-100-treated mem branes of the rat cortex.
A preliminary account of these findings has been presented at the 63rd Annual Meeting of the Japanese Pharmacological Society (8) .
MATERIALS AND METHODS
Preparation of membranes Male Std-Wistar rats (200-250 g) were de capitated. The frontal cortex was dissected and homogenized in 10 volumes of ice-cold 0.32 M sucrose in a Potter-Elvehjem glass homogenizer fitted with a Teflon pestle. The homogenate was centrifuged at 1000 X g for 10 min and the pellet was discarded. The su pernatant was centrifuged at 17,200 X g for 10 min. The crude mitochondrial pellet was re suspended in 20 volumes of Krebs-HEPES buffer and centrifuged at 17,200 X g for 10 min. The pellet (fraction P2) was resuspended in 20 volumes of Krebs-HEPES buffer con taining 0.01-0.1% Triton X-100. After a 30 min incubation at 37°C, the membranes were washed twice by recentrifuging (50,000 X g, 15 min) and resuspending in Triton X-100-free buffer (Krebs-HEPES buffer). The pellet was finally suspended in 40 volumes of the same buffer. A Krebs-HEPES buffer consisting of 25 mM HEPES, 180 mM NaCl, 5 mM KCI, 2.5 mM CaCl2 and 1.2 mM MgCl2 (pH ad justed to 7.4) was used.
Binding assay
Krebs-HEPES buffer (500,ul) with or with out the drug, was added to assay tubes and 100 ul of [3H]quipazine was added at final concentrations of 1.0 nM and 0.3 4.0 nM for drug competition and saturation studies, re spectively. Subsequently, the membrane sus pension (0.2 mg protein/400 ul) was added to initiate binding. The assay tubes were incu bated for 30 min at 25°C. The incubation was terminated by rapid filtration under reduced pressure through Whatman GF/B filters pre soaked in 0.03% polyethyleneimine. The fil ters were immediately washed three times with 4 ml of ice-cold 50 mM Tris-HC1 buffer (pH 7.7).
All experiments were performed in dupli cate or triplicate. Radioactivity was measured by liquid scintillation counting in 10 ml ACS II scintillation cocktail (Amersham). Specific binding was defined as the excess over blanks taken in the presence of 1 uM BRL 43694. Protein concentration was determined by the method of Lowry et al. (9) using bovine serum albumin as a standard.
Drugs
The When the membrane preparation was incu bated for 30 min at 37°C in Triton X-100 solu tion and washed with Triton X-100-free buffer by centrifugation twice, the ratio of specific [3H]quipazine binding to the Triton X-100 treated membranes markedly increased. As shown in Table 1 , the increases in the ratio of specific binding were dependent on the con centration of Triton X-100 in the range of 0.01 -0 .1%. The treatment with more than 0.05% Triton X-100 gave maximal specific binding that was 55 60% of the total binding at 1.0 nM [3H]quipazine. In preliminary experiments a remarkable decrease of specific binding was observed when the membranes were treated with more than 0.1% Triton X-100, such as 0.3% (data not shown). These effects of Tri ton X-100 treatment were observed consistent ly with any batch of [3H]quipazine. The amount of the specific [3H]quipazine binding was linear over a range of membrane protein (25 500 ,u g protein per tube, Fig. 1) .
In saturation analysis of [3H]quipazine bind ing, the specific binding increased with concen trations ranging from 0.3 to 2 nM [3H]quipazine and reached a saturation at higher concentra tions (Fig. 2) Fig. 3 ). The Kd (= K+1/K1) calculated from these rate constants gave a value of 0.83 nM. This Kd value was in close agreement with that obtained from Scatchard analysis. 
DISCUSSION
The major finding of the present study is that treatment of rat cortical membranes with Triton X-100 markedly increased the ratio of specific [3H]quipazine binding to 5-HT3 recep tor sites. The specific binding was only about 30% of the total binding using rat cortical membranes without Triton X-100 treatment.
Under such a condition, it was difficult to esti mate the data of 5-HT3 receptor binding accurately. However, in this study, the ratio of specific binding was increased by treatment of the membrane with Triton X-100 in a concen tration dependent manner. Treatment of the membrane with Triton X-100 (0.5-1.0%) in creased the ratio of specific binding up to 55% of the total binding. Recently, McKernan et al. (10) solubilized 5-HT3 receptor sites from membranes prepared from pooled rat cerebral cortex and hippocampus using various deter gents, and they found that the non-specific binding of [3H]quaternized ICS 205-930 to solubilized 5-HT3 receptor sites to 20% of to tal binding. Therefore, it is supposed that de tergents decrease the non-specific binding in the 5-HT3 receptor binding assay.
To determine if Triton X-100 treated mem branes retain the characteristics of the 5 (2, 3, 5, 13) . Agents that acted on other neurotransmitter receptors were without appreciable affinity for the [3H]quipazine binding sites. These data indicate that Triton X-100-treated membranes retain the character istics of the 5-HT3 binding sites found in the untreated membranes.
We observed the increase in the ratio of specific It is considered that there are mainly two important factors responsible for the increase in the ratio of specific [3H]quipazine binding. One is the decrease of non-specific binding, and the other is the removal of endogenous inhibitors (e.g., 5-HT in this case) from the membrane preparation. In the present study, Triton X-100 treatment decreased non-specific binding of [3H]quipazine in a concentration re lated manner. This indicates that Triton X-100 plays a crucial role in decreasing non-specific binding, probably by preventing non-specific interactions of [3H]quipazine with lipid mole cules in the cortical membranes. Triton X-100 has been frequently used to remove endoge nous inhibitors from the membranes employed in GABA receptor binding studies (15) . The specific [3H]GABA binding to GABA recep tors is enhanced when endogenous GABA was removed from membranes by the treat ment with Triton X-100 (16) . So it is possible that in the present study, Triton X-100 re moved endogenous 5-HT from the membrane preparation. However, the effect of incubation can not be excluded, because the specific binding of [3H]quipazine was increased after incubation at 37°C for 30 min in the prepara tion untreated with Triton X-100.
In conclusion, the present study indicates that Triton X-100 treatment permits highly specific [3H]quipazine binding (55 60% of the total binding). The Triton X-100 treatment should be used for the receptor binding assay using [3H]quipazine, to obtain precise, repro ducable parameters in the 5-HT3 receptor binding study.
